Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies-Reference-Cited by-同舟云学术

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Published:2020-02-01 Issue:2 Volume:77 Page:184
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Luna Gustavo¹,Alping Peter¹²,Burman Joachim³,Fink Katharina²,Fogdell-Hahn Anna²,Gunnarsson Martin⁴,Hillert Jan²,Langer-Gould Annette⁵,Lycke Jan⁶,Nilsson Petra⁷,Salzer Jonatan⁸,Svenningsson Anders⁹,Vrethem Magnus¹⁰,Olsson Tomas²,Piehl Fredrik²¹¹¹²,Frisell Thomas¹

Affiliation:

1. Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

3. Department of Neuroscience, Uppsala University, Uppsala, Sweden

4. Center for Health and Medical Psychology, Örebro University, Örebro, Sweden

5. Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Pasadena

6. Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden

7. Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden

8. Department of Pharmacology and Clinical Neuroscience, Umea University, Umea, Sweden

9. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden

10. Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden

11. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

12. Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2752284/jamaneurology_luna_2019_oi_190084_1630696216.93896.pdf

Reference27 articles.

1. Established and novel disease-modifying treatments in multiple sclerosis.;Cross;J Intern Med,2014

2. A changing treatment landscape for multiple sclerosis: challenges and opportunities.;Piehl;J Intern Med,2014

3. Hospital admission due to infections in multiple sclerosis patients.;Montgomery;Eur J Neurol,2013

4. Safety concerns and risk management of multiple sclerosis therapies.;Soelberg Sorensen;Acta Neurol Scand,2017

5. Disease-modifying therapies and infectious risks in multiple sclerosis.;Winkelmann;Nat Rev Neurol,2016

Cited by 369 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis treatments a review of current biomedical engineering approaches;Biomaterials;2025-02

2. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy;Neurology Neuroimmunology & Neuroinflammation;2024-09

3. Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021;Lupus Science & Medicine;2024-09

4. Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients;eNeurologicalSci;2024-09

5. Data-driven risk/benefit estimator for multiple sclerosis therapies;2024-08-17